AI Article Synopsis
- Clinical investigations in regenerative medicine are exploring various stem cell types to treat a wide range of conditions, with minimal reported safety issues from transplants.
- Many administered stem cells have a temporary presence but can positively affect immune and inflammatory responses.
- Specific stem cell products, like limbal stem cells for eye burns and mesenchymal stem cells for pediatric graft versus host disease, have gained regulatory approvals in certain regions, with more potential applications in clinical trials showing early benefits.
Article Abstract
Clinical investigations using stem cell products in regenerative medicine are addressing a wide spectrum of conditions using a variety of stem cell types. To date, there have been few reports of safety issues arising from autologous or allogeneic transplants. Many cells administered show transient presence for a few days with trophic influences on immune or inflammatory responses. Limbal stem cells have been registered as a product for eye burns in Europe and mesenchymal stem cells have been approved for pediatric graft versus host disease in Canada and New Zealand. Many other applications are progressing in trials, some with early benefits to patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.stem.2015.06.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!